Development of Medical Robots with Kawasaki Heavy Industries
First written in FY2016. 11 of 15 entries say "Advanced", first in FY2021-Q2. Latest entry: FY2026-H1.
The whole theme swung hardest in 2022: 1 of 6 companies on the "Worse" side.
6 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「June 2025: メディカロイド, jointly funded by the company and Kawasaki Heavy Industries,Ltd., the Japanese Surgical Society and NTT Communications Corporation successfully conducted a demonstration of remote robotic surgery using the hinotoriTM Surgical Robot System between Kobe, Hyogo Prefecture, and Strasbourg, France.」
Through collaboration among メディカロイド, the Japanese Surgical Society and NTT Communications, hinotori successfully completed a demonstration of remote robotic surgery between Kobe and Strasbourg. - FY2025-H1AdvancedAnnual report
「April 2024: メディカロイド, jointly funded by the company and Kawasaki Heavy Industries,Ltd., received approval from the Ministry of Health, Labour and Welfare for an indication of the hinotori™ Surgical Robot System in thoracic surgery.」
hinotori™ received approval for an indication in thoracic surgery in addition to its existing indications in urology, gastrointestinal surgery and gynecology, expanding its indications in Japan. - FY2024AdvancedAnnual report
「メディカロイド, jointly funded by the company and Kawasaki Heavy Industries,Ltd., is advancing preparations for the regulatory and sales systems required for global expansion. In July 2023, it began selling an upgraded model equipped with a hand-clutch function, which allows the clutch operation that disconnects the surgical and forceps movements to be controlled by hand in addition to the foot pedal. メディカロイド and its Singapore subsidiary, Medicaroid Asia Pacific Pte. Ltd., obtained sales approval for hinotori from Singapore's Health Sciences Authority in September 2023.」
The company disclosed the launch of a hinotori model equipped with a hand-clutch function and the acquisition of sales approval in Singapore. - FY2024-Q3AdvancedAnnual report
「Finally, in the medical robotics business, メディカロイド, jointly funded by the company and Kawasaki Heavy Industries,Ltd., is advancing preparations for the regulatory and sales systems required for business expansion in Japan and overseas. It has submitted a regulatory application for an indication in thoracic surgery, in addition to the 3 departments in which hinotori™ is currently indicated in Japan: urology, gastrointestinal surgery and gynecology. Going forward, we will coordinate with メディカロイド's regulatory application activities in Japan and overseas and aim to introduce the product sequentially.」
For hinotori™, a regulatory application was submitted for an indication in thoracic surgery, in addition to the existing indications in urology, gastrointestinal surgery and gynecology, marking progress toward expanding its indications. - FY2024-Q2AdvancedAnnual report
「In July 2023, we began selling an upgraded model equipped with a hand-clutch function, which allows the clutch operation that disconnects the surgical and forceps movements to be controlled by hand in addition to the foot pedal. Overseas, メディカロイド and its Singapore subsidiary Medicaroid Asia Pacific Pte. Ltd. obtained sales approval for hinotori™ from Singapore's Health Sciences Authority on 13 September 2023.」
The company began selling an upgraded hinotori™ model equipped with a hand-clutch function and obtained sales approval in Singapore on 13 September 2023. - FY2024-Q1AdvancedAnnual report
「We are advancing preparations for the regulatory and sales systems required for overseas market introduction. On 28 April 2023, メディカロイド, jointly funded by the company and Kawasaki Heavy Industries,Ltd., submitted an application for regulatory approval to Singapore's Health Sciences Authority.」
As part of preparations to introduce hinotori™ in overseas markets, the company submitted an application for regulatory approval to Singapore's Health Sciences Authority. The overseas expansion progressed from the preparation stage to the specific application stage. - FY2023AdvancedAnnual report
「As the global exclusive distributor of hinotori™ Surgical Robot System, developed in Japan, we are promoting its introduction at medical institutions in Japan. In October 2022, the Ministry of Health, Labour and Welfare approved expanded indications in gastrointestinal surgery and gynecology, in addition to urology, and in December 2022 the system became eligible for insurance coverage in those fields.」
hinotori received approval for expanded indications in gastrointestinal surgery and gynecology in addition to urology, and became eligible for insurance coverage in those fields. - FY2023-Q3AdvancedAnnual report
「The system, whose current indication is urology, has received approval from the Ministry of Health, Labour and Welfare for indications in gastrointestinal surgery and gynecology, enabling support for minimally invasive surgery that is less burdensome for patients in additional fields. Preparations for the regulatory and sales systems required for overseas market introduction are also continuing.」
hinotori™ received approval for expanded indications in gastrointestinal surgery and gynecology in addition to its existing urology indication, expanding the fields it can support in Japan. Preparations for the regulatory and sales systems required for overseas market introduction are also continuing. - FY2022RestatedAnnual report
「As the global exclusive distributor of hinotori™ Surgical Robot System, the first surgical robot system developed in Japan, we are promoting its introduction at medical institutions in Japan. Going forward, based on domestic market introduction, we will advance preparations for the regulatory and sales systems required to introduce the product in overseas markets.」
The company has reiterated the domestic introduction of hinotori™ and preparations for the regulatory and sales systems required for introduction in overseas markets. - FY2022-Q2RestatedAnnual report
「The company, the global exclusive distributor of hinotori™ Surgical Robot System, the first domestically produced surgical robot system, is promoting its introduction at medical institutions in Japan. In cooperation with the overseas regulatory approval activities being pursued by メディカロイド, jointly funded by the company and Kawasaki Heavy Industries,Ltd., we will also promote the sequential introduction of the product in overseas markets.」
The company has reiterated the introduction of hinotori™ at medical institutions in Japan and its policy of introducing the product in overseas markets in coordination with efforts to obtain regulatory approvals overseas. - FY2022-Q1RestatedAnnual report
「As the global exclusive distributor of hinotori™ Surgical Robot System, the first domestically produced surgical robot system, we are promoting its introduction at medical institutions in Japan. In cooperation with the overseas regulatory approval activities being pursued by メディカロイド, jointly funded by the company and Kawasaki Heavy Industries,Ltd., we will also promote the sequential introduction of the product in overseas markets.」
The company has reiterated its policy of introducing hinotori™ at medical institutions in Japan and sequentially introducing it in overseas markets in coordination with efforts to obtain regulatory approvals overseas. - FY2021AdvancedAnnual report
「メディカロイド, jointly funded by the company and Kawasaki Heavy Industries,Ltd., received manufacturing and marketing approval for hinotori™, the first domestically produced surgical robot system to receive such approval. As the global exclusive distributor, we launched hinotori™ for medical institutions in Japan, beginning with urology. In cooperation with メディカロイド's efforts to obtain regulatory approvals overseas, we will also promote the sequential introduction of the product in overseas markets.」
Following approval for hinotori™, sales to medical institutions in Japan began with urology, and the company moved to the stage of sequentially introducing the product in overseas markets. - FY2021-Q3AdvancedAnnual report
「メディカロイド, jointly controlled by Kawasaki Heavy Industries,Ltd. and the company, received manufacturing and marketing approval for the hinotori™ Surgical Robot System, the first domestically produced surgical robot system to receive such approval.」
Following regulatory approval for hinotori™, sales to medical institutions in Japan began. The business progressed from the development stage to domestic market introduction. - FY2021-Q2AdvancedAnnual report
「The hinotori™ Surgical Robot System, a surgical robot system developed by メディカロイド, jointly funded by Kawasaki Heavy Industries,Ltd. and the company, received manufacturing and marketing approval in August 2020, the first domestically produced system to do so, and became eligible for coverage under Japan's national health insurance in September 2020. The system is expected to enable smoother surgery by reducing interference between the arms of the operating unit and between the arms and assisting physicians. As メディカロイド's exclusive global distributor, we will sell and service its products worldwide on an exclusive basis. We will initially promote early market introduction in Japan for urology.」
メディカロイド's hinotori™ surgical robot received manufacturing and marketing approval in August 2020 as the first domestically produced system to do so, and became eligible for insurance coverage in September. The company also stated its policy of exclusive global sales and service and its plan to introduce the product in Japan, initially for urology. - FY2016First statedAnnual report
「We also began full-scale development of medical robots through メディカロイド, a joint venture between the company and Kawasaki Heavy Industries,Ltd. (Kobe).」
The company disclosed the start of full-scale development as a new business through the joint venture メディカロイド.